Company intelligence
Absci
Unlocking differentiated biology with generative AI
Biotechnology Research
Vancouver, US
162 employees
Founded 2011
6 public signals
About Absci
Absci is a data-first AI drug creation company designing differentiated therapeutics using generative AI. Our Integrated Drug Creation platform powers cutting-edge de novo AI models and AI lead optimization models aimed at designing better biologics against difficult-to-drug targets.
Verified activity
Signals from Absci
6 published signals
People
Absci is hiring a Senior/Staff AI Scientist for Target Discovery.
Reported by Absci
People
Absci is hiring a Senior/Staff AI Scientist for Antibody Design.
Reported by Absci
Products & Services
Absci's lead asset ABS-201 is currently in Phase 1/2a HEADLINE trial for pattern hair loss.
Reported by Absci
Products & Services
Absci has a woman's health development program ongoing in endometriosis, where diagnosis takes an average of seven years and standard of care is inadequate.
Reported by Absci
Presence & Recognition
Absci spoke with Fierce Biotech about the Apple of Biotech analogy and the commercialization of ABS-201.
Reported by Sean McClain
Research & Knowledge
Absci and its ABS-201 investigational, AI-designed anti-PRLR antibody program were featured in a Bloomberg News segment on innovation in the treatment of hair loss.
Reported by Absci